CD14 and metabolic dysfunction-associated steatotic liver disease: Another study identified changing numbers of CD14+ and CD16+ EVs in NAFLD patients with advanced fibrosis (F3-4) as compared to those with non-severe (F0-2) fibrosis, and the potential of these novel circulating markers to increase the diagnostic utility of the liver fibrosis score (LFS) (142).